Use of H19 Gene Regulatory Sequences in DNA-Based  Therapy for Pancreatic Cancer

<table>H19 RNA level in human and hamster pancreatic carcinoma cell lines. (a) Lane 1: 100 bp marker, Lane 2: CRL-1469 cells, Lane 3: PC.1-0 hamster cells. (b) Lane 1: 100 bp marker, Lanes 2–5: CRL-2547, CRL-1687, CRL-2119, and CRL-1997 human pancreatic carcinoma cells, respectively. (c) Lane 1: 100 bp marker; Lane 2: mouse control; Lane 3: PC.1-0 cells cultured under normoxia conditions; Lane 4: PC.1-0 cells cultured under hypoxia condition for 4 hours; Lane 5: tumors generated by PC.1-0 cells injection into nude mice back; Lane 6: negative control, no cDNA is present in the reaction mixture. The upper and the middle panels show the 228 bp and the 454 bp PCR products, respectively, obtained using two different primers (H19-mouse 228 and H19-mouse 454 as described in Supplementary data, Table <svg height="10.6625" id="M23" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 11.4125 10.6625" width="11.4125" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,10.6625)">
<g transform="translate(72,-63.47)">
<text transform="matrix(1,0,0,-1,-71.95,63.52)">
<tspan style="font-size: 12.50px; " x="0" y="0">A</tspan>
</text>
</g>
</g>
</svg>). The lower panel indicates the 400 bp <svg height="13.425" id="M24" style="vertical-align:-2.29482pt" version="1.1" viewbox="0 0 8.8500004 13.425" width="8.8500004" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,13.425)">
<g transform="translate(72,-61.26)">
<text transform="matrix(1,0,0,-1,-71.95,63.6)">
<tspan style="font-size: 12.50px; " x="0" y="0">𝛽</tspan>
</text>
</g>
</g>
</svg>-actin internal control.</table>

Journal of Oncology

fig2

Figure 2

Figure 2: Use of H19 Gene Regulatory Sequences in DNA-Based  Therapy for Pancreatic Cancer 